Back to discover
Drug

Oprelvekin

Established medicine
ClassInterleukin 11 receptor alpha agonistResearchOngoing clinical research

Also known as IL-11, Neumega, Oprelvekin (rhIL-11), Recombinant interleukin-11.

RxNorm139994ChEMBLCHEMBL1201573ATCL03AC02UNIIHM5641GA6F
IL11RA
Primary target
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Phase II Biologic Effects Study of Recombinant Interleukin-11 (rhIL-11, Neumega) in Subjects With Moderate or Mild Hemophilia A, or Von Willebrand Disease Unable to Use DDAVP

Clinical trial2016-03-02Results posted · ClinicalTrials.gov

Study Of The Effects Of Oprelvekin On Cardiac Repolarization In Subjects At Risk Of Severe Thrombocytopenia After Myelosuppressive Chemotherapy

Clinical trial2015-12-01Terminated · ClinicalTrials.gov

Phase II Clinical Efficacy Trial of Recombinant Interleukin-11 (rhIL-11, Neumega) in Subjects With Type 1 Von Willebrand Disease Undergoing Surgery

Clinical trial2012-06-01Terminated · ClinicalTrials.gov

Phase I/II Study of Two Sequential Doses of IDEC-Y2B8 in Patients With Relapsed Low-Grade and Follicular Non-Hodgkin's Lymphoma

Clinical trial2010-04-01Terminated · ClinicalTrials.gov

Phase II Comparison Study of Hemostatic Efficacy of Escalating Doses of Interleukin-11 (rhIL-11, Neumega) in Subjects With Type 1 Von Willebrand Disease

Clinical trial2007-12-01Completed · ClinicalTrials.gov

Combination of Interleukin 11 (Neumega) With G-CSF to Mobilize Autologous Peripheral Blood Stem Cells (PBSC)

Clinical trial2002-04-01Completed · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Oprelvekin
Aliases & brands
IL-11NeumegaOprelvekin (rhIL-11)Recombinant interleukin-11
RxNorm CUI
139994
ChEMBL ID
CHEMBL1201573
ATC codes
L03AC02
UNII
HM5641GA6F
Primary mechanism
Interleukin 11 receptor alpha agonist

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Interleukin-11 receptor subunit alpha
IL11RA · Q14626
AGONISTInterleukin 11 receptor alpha agonist

Clinical trials

6 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
6
registered trials across all phases
LATEST COMPLETION 2012
3
Completed
3
Discontinued
PHASE DISTRIBUTIONn = 6
Phase 1 / 21Phase 25
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • ClinicalTrials.gov — clinical trials